Jump to content
 







Main menu
   


Navigation  



Main page
Contents
Current events
Random article
About Wikipedia
Contact us
Donate
 




Contribute  



Help
Learn to edit
Community portal
Recent changes
Upload file
 








Search  



























Create account

Log in
 









Create account
 Log in
 




Pages for logged out editors learn more  



Contributions
Talk
 



















Contents

   



(Top)
 


1 Eutectic mixture  





2 Clinical use  



2.1  Indications  





2.2  Dosage forms  





2.3  Circumcision  







3 Tempe  





4 Compendial status  





5 See also  





6 References  





7 External links  














Lidocaine/prilocaine






تۆرکجه
Français
Italiano
Nederlands
Српски / srpski
Srpskohrvatski / српскохрватски
Tiếng Vit
 

Edit links
 









Article
Talk
 

















Read
Edit
View history
 








Tools
   


Actions  



Read
Edit
View history
 




General  



What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Cite this page
Get shortened URL
Download QR code
Wikidata item
 




Print/export  



Download as PDF
Printable version
 


















From Wikipedia, the free encyclopedia
 


Lidocaine/prilocaine
Combination of
LidocaineLocal anesthetic
PrilocaineLocal anesthetic
Clinical data
Trade namesEmla, Fortacin, Senstend, others
AHFS/Drugs.comMicromedex Detailed Consumer Information
License data
  • US DailyMedLidocaine_and_prilocaine
  • Routes of
    administration
    Topical
    ATC code
    • None
    Legal status
    Legal status
  • US: ℞-only
  • EU: Rx-only[4]
  • Identifiers
    CAS Number
    PubChem CID
    ChemSpider
    KEGG
    CompTox Dashboard (EPA)
     ☒NcheckY (what is this?)  (verify)

    Lidocaine/prilocaine is a eutectic mixture of equal quantities (by weight) of lidocaine and prilocaine. A 5% emulsion preparation, containing 2.5% each of lidocaine/prilocaine, is marketed by APP Pharmaceuticals under the trade name EMLA (an abbreviation for Eutectic Mixture of Local Anesthetics).[5] As a spray, it is marketed under the name Tempe (topical eutectic-like mixture for premature ejaculation) (PSD502) that can be used by men to help with premature ejaculation. The spray is manufactured by Plethora Solutions and branded as Fortacin in the UK and Recordati in the EU.[6]

    Eutectic mixture[edit]

    Separately, lidocaine and prilocaine are solid bases. When mixed in equal quantities by weight, however, they form a eutectic mixture – that is the melting point of the mixture is lower than the melting points of the individual components. The lidocaine/prilocaine eutectic mixture is an oil with a melting point of 18 °C, and can be formulated into preparations without the use of a non-aqueous solvent.[7] This allows higher concentrations of anaesthetic to be formulated into the preparation and maintained during application.

    Clinical use[edit]

    Indications[edit]

    The lidocaine/prilocaine combination is indicated for dermal anaesthesia. Specifically it is applied to prevent pain associated with intravenous catheter insertion, blood sampling, superficial surgical procedures, and topical anaesthesia of leg ulcers for cleansing or debridement.[8] Also, it can be used to numb the skin before tattooing as well as electrolysis and laser hair removal. It is also sometimes used in advance of injected local anaesthetics for minor surgery and biopsies.

    A topical spray consisting of an aerosol formulation of lidocaine and prilocaine was evaluated under the name PSD502 for use in treating premature ejaculation. The spray is applied on the penile skin prior to intercourse. While this formulation was not approved by the FDA,[9] a similar product, Promescent, is available over-the-counter in the U.S.

    Dosage forms[edit]

    Lidocaine/prilocaine eutectic mixture is marketed as a 5% oil-in-water emulsion incorporated in a cream base (EMLA cream) or a cellulose disk (EMLA patch). The cream is applied under an occlusive dressing, while the patch incorporates an occlusive dressing to facilitate absorption of lidocaine and prilocaine into the area where anaesthesia is required. Local dermal anaesthesia is achieved after approximately 60 minutes, whereupon the occlusive dressing (or patch) is removed. The duration of anaesthesia is approximately two hours following removal of the occlusive dressing.

    E. Fougera & Co., makers of the generic cream widely used in the United States as Lidocaine and Prilocaine Cream, 2.5%/2.5%, recommends different timing for application of the cream as well as length of anesthesia. They state the cream must be applied at least one hour before the start of a routine procedure and for two hours before the start of a painful procedure. Additionally, they state that the duration of effective skin anesthesia will be at least one hour after removal of the occlusive dressing.[10]

    Circumcision[edit]

    Lidocaine/prilocaine eutectic mixture has been used during circumcision in newborn boys and has been considered efficacious and safe to lessen pain from circumcision.[11]

    The European Medicines Agency concludes in its latest (2014) statement on Emla: "Safety and efficacy for the use of EMLA on genital skin and genital mucosa have not been established in children younger than 12 years. Available paediatric data do not demonstrate adequate efficacy for circumcision."[12]

    The Patient Information Leaflet of EMLA in the UK states: "EMLA Cream should not be applied to the genital skin (e.g. penis) and genital mucosa (e.g. in the vagina) of children (below 12 years of age) owing to insufficient data on absorption of active substances."[13]

    Tempe[edit]

    The spray is a combination of local anaesthetics lidocaine and prilocaine in a metered-dose aerosol that is sprayed directly on the penis to numb sensations. It was developed by the same group that invented the erectile dysfunction drug sildenafil.[citation needed] The drug was approved in Europe and was released in the UK market in November 2016 and within the EU will be marketed by, early in 2017[14][unreliable medical source?] In the United States, the Food and Drug Administration (FDA) is expected to approve the drug in 2018.[15][unreliable medical source?]

    Compendial status[edit]

    See also[edit]

    References[edit]

    1. ^ "Emla Cream 5% (for 5 g and pre-medication packs) - Summary of Product Characteristics (SmPC)". (emc). 4 May 2017. Retrieved 27 September 2020.
  • ^ "Fortacin - Summary of Product Characteristics (SmPC)". (emc). 14 November 2018. Retrieved 27 September 2020.
  • ^ "Nulbia 5% cream - Summary of Product Characteristics (SmPC)". (emc). 18 December 2017. Retrieved 27 September 2020.
  • ^ "List of nationally authorised medicinal products" (PDF). ema.europa.eu. 1 December 2022. Retrieved 13 June 2023.
  • ^ Pesaturo KA, Matthews M (2009). "Topical Anesthesia Use in Children: Eutectic Mixture of Local Anesthetics". US Pharm. 34 (3): HS-4. Retrieved 7 January 2014.
  • ^ Dinsmore WW, Wyllie MG (April 2009). "PSD502 improves ejaculatory latency, control and sexual satisfaction when applied topically 5 min before intercourse in men with premature ejaculation: results of a phase III, multicentre, double-blind, placebo-controlled study". BJU International. 103 (7): 940–949. doi:10.1111/j.1464-410X.2009.08456.x. PMID 19245438. S2CID 205540753.
  • ^ "EMLA Official FDA information, side effects and uses". Drugs.com. Retrieved 7 January 2014.
  • ^ Heinen MM, van Achterberg T, op Reimer WS, van de Kerkhof PC, de Laat E (March 2004). "Venous leg ulcer patients: a review of the literature on lifestyle and pain-related interventions". Journal of Clinical Nursing. 13 (3): 355–366. doi:10.1046/j.1365-2702.2003.00887.x. PMID 15009338.
  • ^ "PSD502 TEMPE Spray". Promescent.com. Retrieved 4 July 2014.
  • ^ Lidocaine and Prilocaine Cream, 2.5%/2.5%, package insert. E. Fougera & Co. package insert. Melville, New York, 9/2007.
  • ^ Taddio A, Ohlsson K, Ohlsson A (2000). Ohlsson A (ed.). "Lidocaine-prilocaine cream for analgesia during circumcision in newborn boys". The Cochrane Database of Systematic Reviews (2): CD000496. doi:10.1002/14651858.CD000496. PMID 10796371. (Retracted, see doi:10.1002/14651858.cd000496.pub2. If this is an intentional citation to a retracted paper, please replace {{retracted|...}} with {{retracted|...|intentional=yes}}.)
  • ^ "INN of the active substance(s): lidocaine/prilocaine" (PDF). Committee for Medicinal Products for Human Use (CHMP). European Medicines Agency.
  • ^ "Package leaflet: Information for the user EMLA Cream 5%" (PDF). AstraZeneca. 2017.
  • ^ "TEMPE Spray Delays Ejaculation". bio-medicine.org. Archived from the original on 27 September 2013. Retrieved 25 September 2013.
  • ^ "Viagra Inventor Develops 'Tempe Spray' To Help Men Deal With Premature Ejaculation: Is It Safe?". medicaldaily.com. 24 September 2013. Retrieved 25 September 2013.
  • ^ The United States Pharmacopeial Convention. "Revision Bulletin: Lidocaine and Prilocaine Cream–Revision to Related Compounds Test". Archived from the original on 5 July 2010. Retrieved 10 July 2009.
  • External links[edit]


    Retrieved from "https://en.wikipedia.org/w/index.php?title=Lidocaine/prilocaine&oldid=1190942722"

    Categories: 
    Drugs not assigned an ATC code
    Local anesthetics
    Combination drugs
    Drugs developed by AstraZeneca
    Products introduced in 2013
    Hidden categories: 
    Articles unintentionally citing retracted publications
    Articles with short description
    Short description matches Wikidata
    Use dmy dates from June 2023
    Articles needing additional references from July 2009
    All articles needing additional references
    Drugs with non-standard legal status
    Articles without EBI source
    Chemical pages without DrugBank identifier
    Articles without InChI source
    Articles without UNII source
    Drug has EMA link
    Drugboxes which contain changes to verified fields
    Drugboxes which contain changes to watched fields
    Drugs that are a combination of chemicals
    All articles with unsourced statements
    Articles with unsourced statements from September 2020
    All articles lacking reliable references
    Articles lacking reliable references from November 2017
    Articles with J9U identifiers
    Articles with LCCN identifiers
     



    This page was last edited on 20 December 2023, at 19:22 (UTC).

    Text is available under the Creative Commons Attribution-ShareAlike License 4.0; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.



    Privacy policy

    About Wikipedia

    Disclaimers

    Contact Wikipedia

    Code of Conduct

    Developers

    Statistics

    Cookie statement

    Mobile view



    Wikimedia Foundation
    Powered by MediaWiki